Novo Nordisk A/S
Copenhagen : NOVO B

February 02, 2012 01:44 ET

Novo Nordisk A/S: Financial Statement - Novo Nordisk increased operating profit by 18% in 2011

BAGSVAERD, DENMARK--(Marketwire - Feb 2, 2012) -

Sales growth of 9% driven by Victoza®, NovoRapid® and Levemir®

Company Announcement no 7 / 2012: http://hugin.info/2013/R/1581997/494216.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE

[HUG#1581997]

Contact Information

  • Media:

    Mike Rulis
    Tel: (+45) 4442 3573
    Email Contact

    In North America
    Ken Inchausti
    Tel: (+1) 609 786 8316
    Email Contact

    Investors:
    Klaus Bulow Davidsen
    Tel: (+45) 4442 3176
    Email Contact

    Frank Daniel Mersebach
    Tel: (+45) 4442 0604
    Email Contact

    Lars Borup Jacobsen
    Tel: (+45) 3075 3479
    Email Contact

    Jannick Lindegaard
    Tel: (+1) 609 786 4575
    Email Contact

    Further information about Novo Nordisk is available on the company's website
    novonordisk.com